Get notified when OKUR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The auditor's report includes a going-concern warning, indicating substantial doubt about the company's ability to continue operating.
OnKure Therapeutics prices $55M IPO at $8/share, plus $5M private placement to Abingworth
Filed May 4, 2023 · ~1 min read
Key Changes
-
high
OnKure is selling 6,875,000 shares at $8.00 per share for $55.0M gross; net proceeds to the company are $50.5M.
The Offering verify on EDGAR → -
high
A concurrent private placement to Abingworth Bioventures 8 LP adds 625,000 shares at $8.00 for $5.0M gross, with net proceeds of about $4.7M.
Use of Proceeds verify on EDGAR → -
high
Proceeds will fund mavodelpar development for PMM and LC-FAOD, regulatory submissions, and commercialization preparation.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PLAY 10-Q) is open in full — no account needed.
Partner
Trade OKUR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify